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l Introduction
Isoxsuprine and other sympathomimetic drugs are
now frequently used to inhibit premature labor [4,
9, 15, 16, 17]. The tocolytic properties of these
agents are attributed to their 62 stimulatory effect
which reduces the strength and frequency of con-
traction of uterine muscle. While much of the
cardiovascular effects of these agents upon the
mother and fetus has been identified [3,5,6, 21],
less is known about their effect upon glucose
metabolism. Neonates delivered of women who
received B sympathomimetic drugs are at increased
risk of developing hyppglycemia [2, 7]. Several
alterations in fetal and maternal glucose homeo-
stasis may be related to this development. Mater-
nal and fetal hyperglycemia has been reported to
develop with the administration of B sympatho-
mimetics to women [18, 26]. The increase in fetal
glucose may be a direct drug effect upon the fetus
äs suggested by the observation that fetal hyper-
glycemia develops during infusion of fenoterol
directly to the sheep fetus [6]. EPSTEIN et al.
found elevated insulin concentrations in the cord
plasma of infants whose mothers had received B-
sympathomimetic agents and suggested that fetal
hyperglycemia resulting in excessive insulin pro-
duction might be responsible for neonatal hypo-
glycemia [7]. Because of the morbidity which
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results from hypoglycemia, further elucidation of
the means by which B sympathomimetic tocolytic
agents alter glucose metabolism seemed warranted.
For this reason, this study has employed the un-
restrained, awake rat model to determine the
effects of isoxsuprine infusion upon the glucose
and insulin production öf the mother, fetus and
neonate.
2 Materials and methods
2.1 Animals
Primiparous pregnant and age-matched virgin fe-
males were obtained from Charles River Labora-
tories, Wilmington, Massachusetts. The pregnant
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© by Walter de Gruyter & Co. · Berlin · New York
294 Ogata, Isoxsuprine Infusion in the rat
rats had been mated at 47 days of age and this was
designated äs day 0 of gestation (Gestational
period = 21& days). On day 15 of gestation, rats
were anesthetized with an intraperitoneal injection
of chloral hydrate (30 mg/100 g body weight) and
a pre-formed silastic catheter was implanted in the
jugular vein. The catheter was placed subcutane-
ously with the distal end sutured to the dorsum of
the rät's neck. The catheter was filled with 0.1 ml
of polyvinylpyrolidone containing heparin (.65 mg
polyvinylpyrolidone was mixed with l ml of 0.9%
saline and 25 units heparin) [22]. This polymer
maintains catheter patency for a week or more and
is aspirated from the catheter at time of infusion.
Only rats who consistently grained weight follow-
ing catheterization (pregnants, 10 g/day; virgins,
x
 3—5 g/day) were studied. In addition, for maternal
and neonatal studies, only rats which had 8 to 12
pups in a litter were used. All rats had ad libitum
access to food (Purina Rat Chow). Pregnant rats
weighed 301 ± 20 and virgin rats 268 ±18 grams
at time of infusion.
2.2 Infusion and newborn care
Rats were infused at 0900 of day 21 of gestation.
Pregnant and age-matched virgin received either
isoxsuprine (Vasodilan, ME AD JOHNSON, Evans-
ville, Indiana) or 0.04 M saline. Isoxsuprine was
administered äs a bolus (0.11 mg/100 gram body
weight) followed by a continuous infusion
(0.11 mg/100 gram body weight/hour) for 3 hours
to pregnant and virgin rats. Control pregnant and
virgin rats received 0.04 M saline in volumes equi-
valent to the isoxsuprine Solutions. Isoxsuprine
concentration was .33 mg/ml in 0.04 M saline.
Thus, depending upon body weight, pregnant rats
received from 0.9 to 1.1 ml fluid äs a bolus and
from 2 to 3.4 ml during the 3 hour infusion.
Virgin rats received from 0.7 to 1.0 ml fluid äs a
bolus and 2 to 3 ml during infusion. Experiments
were performed with individual pumps for each
rat. All infusions were conducted at room tem-
perature (22-24 ° C).
Doses for isoxsuprine administration in humans
vary from 3-6 mg for loading and 6-18 mg/hr for
maintenance. Drug therapy must be individualized
because of cardiovascular effects. To determine
doses for the rats in this experiment, the effect of
isoxsuprine upon blood pressure was established in
preliminary experiments. The systolic blood pres-
sure of restrained, pregnant and virgin rats ranged
from 50—70 torr äs measured with a Rodent Pro-
grammed Electro Sphygomanometer (PE-300,
NARCO BIOSYSTEMS Inc., Houston, Texas) cali-
brated to 100 torr. Pregnant and virgin rats who
received maintenance doses of 0.16 mg/100 g/hour
or greater became pale and inactive and had sys-
tolic blood pressures of 30—40 torr. Rats receiving
the 0.11 mg/100 g/hr maintenance dose consist-
ently maintained blood pressures of 50—60 torr.
For this reason, the latter dose, which is 10 times
greater than the dose recommended for humans,
was used for the entire experiment.
Rats were attached to pump tubing by means of a
swivel and harness so that they were allowed un-
restrained activity. Prior to and at intervals during
the infusion, blood samples were obtained from
the cut tau tip. The tip of the tau was gently re-
warmed at each sampling to establish free blood
flow. Rats were decäpitated at the end of the infu-
sion, and fetuses and placentas removed from the
uterus. The umbilical cords were immediately cut,
the pups dried and placed in an incubator set at
36 °C and 50% humidity. All rat pups weighed be-
tween 5.2-5.8 grams and placentas 0.6-.07 grams.
To insure uniformity of measurements, only pups
from litters with 8 to 12 pups were used. The
weight and the appearance of the pups suggested
that they were at term gestation.
Blood was collected from newborn rat pups by
cutting the axillary vessels and collecting free flow-
ing blood in heparinized tubes. One or two pups
from each litter were killed at each point so that
serial measurements of offspring from one mother
could be made during the neonatal period.
Maternal and newborn liver samples were imme-
diately frozen in liquid nitrogen.
2.3 Analysis
Plasma glucose concentrations were determined
with a BECKMAN II Glucose Analyzer and insulin
concentrations by a modificatioü of the technique
of SOELDNER and SLONE [25]: Hepatic glycogen
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concentrations were determined by the method of
VAN HANDEL [27].
Plasma isoxsuprine concentrations were deter-
mined by NUCLEAR MEDICAL SYSTEMS, Inc.,
Newport Beach, California with a double antibody
radioimmunoassay technique. Plasma was initially
treated with diethyl ether to extract protein since
isoxsuprine is predominantly protein bound.
Eight virgin and sixteen pregnant rats were in-
cluded in each of the saline and isoxsuprine in-
fused groups. More pregnant rats were required
because serial measurements of glucose and insulin
were made from litter mates of isoxsuprine or
saline infused mothers and limited amounts of
blood could be obtained from each rat pup. Values
for metabolic variables in newborn rats represent
serial measurements from pups of individuallittersl
Eight litters are represented in the serial measure-
ment of each variable.
Plasma samples from an additional 4 maternal rats
and their offspring were analyzed for plasma isox-
suprine determination.
The "Student's" unpaired T test was used to com-
pare differences between groups and the paired T
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3 Results
Isoxsuprine infusion did not result in any deaths,
and all rats displayed apparently normal activity
during infusion. None of the pregnant rats de-
livered during infusion of either isoxsuprine or
0.04 M saline.
Fig. l indicates changes in plasma glucose con-
centrations in pregnant and virgin rats. Before
infusion, pregnant rats had a mean plasma glucose
of 99 ± 7 mg/dl. This was significantly less than
values for virgin rats (120 ± 8 mg/dl, p < 0.01).
Isoxsuprine infusion increased plasma glucose con-
centrations in both pregnant and virgin rats, and
virgin rats receiving isoxsuprine demonstrated
greater increases above preinfusion values than
pregnant rats. In both pregnant and virgin rats
receiving isoxsuprine, plasma glucose concentra-
tions tended to decrease during the 3 hour infu-
sion however, the values at 180 minutes were not
significantly less than the 30 minute values.
VIRGIN
30 60 120 180 0 30 60
TIME(minutes)
120 180
Fig. 1. Plasma glucose concentrations in pregnant and virgin rats infused with isoxsuprine (solid line) or 0.04 M saline
(dotted line). Before infusion, pregnant rats had significantly lower plasma glucose concentrations than virgin rats
(p < 0.01). Isoxsuprine infusion resulted in significant increases in plasma glucose (p < 0.001) above saline infusion
values in both pregnant and virgin rats. Values for virgin rats during isoxsuprine infusion were significantly greater than
for pregnant rats (p < 0.001). Values for saline infused virgins remained significantly greater than for saline infused
pregnant rats (p < 0.05). Eight rats were included in each of the virgin groups and 16 rats in each of the pregnant
groups.
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Pregnant rats had significantly greater plasma in-
sulin concentrations before Infusion than virgin
rats (Fig. 2). Isoxsuprine Infusion was associated
with a significant increase in plasma insulin in both
pregnant and virgin rats. Thirty minutes following
Initiation of isoxsuprine Infusion, pregnant rats
demonstrated a 35% increase and virgin rats a 60%
increase in insulin concentrations. Values in isox-
suprine infused rats remained elevated throughout
the infusion.
At the end of the infusion, liver glycogen con-
centrations in rats who received saline were equi-
valent (pregnant 36 ± 4 mg/g wet liver and virgin
40 ± 6 mg/g wet liver). Rats who received isox-
suprine had significantly less hepatic glycogen and
values were equivalent in pregnant and virgin rats
v(18 ± 8 mg/g wet liver and 16 ± 8 mg/g wet liver
respectively.
Tab. I presents measurements from newborn rat
pups of maternal rats who were infused with either
isoxsuprine or saline. Pups of isoxsuprine infused
mothers had significantly greater plasma glucose
concentrations at birth and at l and 4 hours of age
compared to pups of saline infused mothers. By 7
and 11 hours, glucose concentrations were signif-
icantly less in the pups of isoxsuprine infused
mothers. By 16 hours of age, both groups had very
low glucose concentrations which did not differ.
Hepatic glycogen concentrations were significantly
less in pups of isoxsuprine infused mothers than of
saline infused mothers at birth and a l and 4 hours
of age. Values for both groups decreased signif-
icantly from preceding values at 7 hours and there
were no differences in the very low values at 11
and 16 hours.
Plasma insulin concentrations were elevated in
pups of isoxsuprine infused mothers at birth and
at l hour of age. No difference in insulin con-
centrations occurred after this point.
Isoxsuprine concentration was determined in serial
plasma samples from 4 pregnant rats and their off-
spring. Thirty minutes after administration of the
leading dose and following initiation of the infu-
sion, plasma isoxsuprine concentrations were
33,893 ±'4301 pcg/ml (r nge 25,500-39,725 pcg/
ml). By 60 minutes, values were somewhat less
(28,589 ± 2810 pcg/ml, r nge 25,660-34,208 pcg/
ml). Values at 180 minutes were simil r (29,808
± 2033 pcg/ml, r nge 24,560-35,400 pcg/ml).
Plasma concentrations in newborn rat pups at
delivery were 25,762 ± 4370 pcg/ml (r nge 19,330
-30,303 pcg/ml). These values were 80 to 86% of
the maternal values at time of delivery. At 4 hours
concentrations had decreased to 19,934 ±
5910 pcg/ml (r nge 16,543-23,400 pcg/ml). By
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Fig. 2. Plasma insulin concentrations in pregnant and virgin rats infused with isoxsuprine (solid line) or 0.04 M saline
(dotted line). Before infusion, pregnant rats had significantly greater plasma insulin concentrations than virgin rats
(p < 0.01). Isoxsuprine infusion resulted in a significant and sustained increase of plasma insulin above saline infusion
values in both pregnant and virgin rats (p < 0.01). Eight rats were included in each of the virgin groups and 16 rats in
each of the pregnant groups.
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Tab. I. Metabolie variables in rat pups of isoxsuprine and saune infused mothers
Glucose (mg/dl)
Isoxsuprine
Saline
Age
0
90i
***
54 t
(Hours)
5
5
1
80 ± 8
***
30 ±8
4
53 ±7
**
34 ±8
7
30 ±7
**
60 ±8
11
20 ±6
*
40 ±5
16
20 ±
18 i
8
7
Hepatic glycogen (mg/g wet liver)
Isoxsuprine
Saline
40 ±9
***
80 ± 12
35 ±8
***
64 ±3
28 t 6
**
58 ±6
18 ±5
18 ±6
6± l
6 ± 1
6 ± 1
4 ± 1
Insulin (ng/ml)
Isoxsuprine
Saline
8.4 ± .2
***
6.2 ± .3
8.0 ± .5
**
1.7 ±.3
2.0 ± .3
1.3 ± .4
1.0 ± .3
1.2 ±.4
1.1 ± .3
1.3 ± .4
.7 ± . 2
.6± . l
* The asterisks denote degrees of difference between isoxsuprine and saline infused pups
(***-p<0.001; **-p<0.01; *-p<.05)
Serial measurements in litter mates from 8 maternal rats aie included in each group.
16 hours, values were 14,350 ± 2000 pcg/ml
(ränge 11,303-16,101 pcg/ml).
4 Discussion
The intent of this study was to measure the short
term effects of isoxsuprine administration upon
maternal and neonatal glucose metabolism. This
study in some ways mimics the clinical Situation in
which tocolytic therapy is administered to the
woman in premature labor but falls to prevent
delivery. We used the laboratory rat because in
some aspects of metabolic development, the rat
pup at term is siinilar to the premature human
neonate. With respect to glucose metabolism, both
have poorly developed hepatic and renal enzyme
Systems for glucose production and 'both have
limited ability to mobilize insulin [11,13,14,24],
We should also point out that the isoxsuprine dose
used in this study far exceeded the recommenda-
tions for tocolytic therapy in humans; however,
our experimentai animals did not develop hypoten-
sion.
Isoxsuprine infusion to the maternal and non-
gravid rats almost immediately increased plasma
glucose concentrations. The associated decrease in
hepatic glycogen indicates that enhanced glyco-
genolysis is at least partly responsible for this
glycemic response. While the exact mechanism by
which isoxsuprine stimulates glucose production is
unknown, the results of a study by ESTEBAN-
ALTIRRIBA et al. [8] suggest that the glycemic
effect represents a direct beta Stimulation of
glucose production by isoxsuprine. They found
that the glucose mobilizing effects of ritrodrine, a
beta sympathomimetic drug similar to isoxsuprine,
can be blocked by the administration of practolol,
a beta agonist. The present study suggests that
isoxsuprine did not stimulate glucose production
by inhibiting pancreatic insulin production since
maternal insulin concentrations actually increased
with infusion. The increase in insulin thus repre-
sents a response to glucose production and may
also represent a direct Stimulation of the pancreatic
insulin production of isoxsuprine [10].
Isoxsuprine administration reduced hepatic gly-
cogen concentrations to equivalent degrees in both
J. Perinat. M ed. 9 (1981)
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pregnant and nongravid rats. These values were
extremely low and indicate that 3 hours of isox-
suprine Infusion almost completely depleted
hepatic glycogen in both pregnant and nongravid
rats. Pregnant rats, however, did not increase
plasma glucose concentrations äs much äs non-
gravid rats. This suggests that the pregnant rat had
greater demands upon its glucose reserve than the
nongravid and most likely represents the con-
tinous drain of glucose by conceptus. The lower
glucose and higher insulin concentrations in the
fed pregnant rat compared to the virgin rat agree
with earlier reports [19]. This observation is also
consistent with the concept that the state of
pregnancy results in a drain of maternal glucose
to the conceptus and that "extra" maternal insulin
'is necessary to preserve maternal glucose stores
[20].
The documentation of substantial concentrations
of isoxsuprine in fetal plasma at delivery indicates
that maternal administration can result in isox^
suprine delivery to the fetus. Rat pups delivered
of isoxsuprine infused mothers had significantly
greater glucose concentrations and lower hepatic
glycogen concentrations for the first 4 hours of
life than pups of saline infused mothers. Since
isoxsuprine was present in neonatal plasma, these
observations suggest that isoxsuprine might have
directly stimulated glycogenolysis in the rat fetus.
This in utero depletion of glycogen would thenbe
responsible for the significant decrease in neonatal
plasma glucose which occurred at 7 hours of age.
Another potential mechanism for the development
of the decrease in newborn plasma glucose con-
centrations was the isoxsuprine Stimulation of
maternal glucose production which resulted in in-
creased availability of maternal glucose to the
fetus and Stimulation of fetal insulin production.
This possibility would agree with the findings of
EPSTEIN et al. [7] who reported that infants of
women who received B sympathomimetic therapy
had elevated insulin concentrations in cord blood.
It is unclear however whether hyperinsulinism con-
tributes to the development of hypoglycemia in
the neonate since in this study, hyperinsulinism
did not continue beyond 4 hours of life. Likewise,
insulin measurements at the actual time of isox-
suprine-associated hypoglVcemia have not been
reported in human neonates.
Newborn rat pups of isoxsuprine infused mothers
had a significant decrease in plasma glucose con-
centration at 7 hours of age and had significantly
less hepatic glycogen stores at birth compared to
rats of saline infused mothers. This suggests that
in utero depletion of hepatic glycogen stores was
responsible for the development of relative hypo-
glycemia at 7 and 11 hours of life in the offspring
of isoxsuprine treated rats. By 11 hours of age, rat
pups of saline-infused mothers had also depleted
their hepatic glycogen stores and by 16 hours of
life, demonstrated a profound increase in plasma
glucose. These changes are similar to observations
by GIRARD et al. [12] who also demonstrated that j
during fasting in the neonatal period, rats mobilize ;
glycogen t o maintain glucose homeostasis but are
unable to perform gluconeogenesis despite having
an adequate quantity of gluconeogenic enzymes.
Since premature human infants also are limited in |!
their ability to perform gluconeogenesis, it is
possible that human neonates of isoxsuprine
treated mothers become hypoglycemic because of
in utero glycogen depletion.
The limited preliminary values showing that rat
pups at birth had plasma isoxsuprine concentra-
tions approximately 80 to 86% of maternal con-
centrations shows that much placental transfer of
this substance occurred during 3 hours of infusion.
The lower concentrations at 16 hours of age sug-
gest that the newborn rat pups can clear isox-
suprine from the intravascular space. The mecha-
nism of this process is unknown.
It has been suggested that if B sympathomimetic
therapy stimulates fetal hyperglycemia and hyper-
insulinism, prolonged therapy might result in fetal
macrosomia. BLOUN et al. [1] tested this hypo-
thesis by administering ritrodrine orally to women
with normal carbohydrate metabolism from the
25th week of gestation until delivery. None of the
offspring of these women demonstrated increased
birth weight. This study did not address this partic-
ular question since isoxsuprine was administered
acutely to maternal rats at term. Under this Situa-
tion, the offspring of isoxsuprine and saline in-
fused rats did not differ in weight.
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A variety of cardiovascular effects of maternal B
sympathomimetic administration have been de-
scribed [3, 5, 6, 2l]. Uterine blood flow usually
increases and systemic blood pressure may be im-
affected or decrease. By adjusting isoxsuprine
doses, this study attempted to avoid this latter
complication. The role of these cardiovascular
alterations in affecting glucose delivery to the fetus
and altering fetal glucose homeostasis remains un-
known.
These findings suggest that maternal isoxsuprine
infusion depletes maternal and fetal hepatic
glycogen stores and that the resultant hyper-
glycemia stimulates maternal and fetal insulin
production. The in utero depletion of hepatic
glycogen stores initially causes hyperglycemia
and places the newborn rat pup at risk of later
developing hypoglycemia. A similar sequence of
events might be responsible for the development
of hypoglycemia in the human offspring of isox-
suprine-infused mothers. Clinical studies including
frequent measurement of plasma glucose and
insulin concentrations and assessment of glucose
turnover would be necessary to answer this ques-
tion.
Summary
To determine the mechanism of alteration in glucose
homeostasis associated with maternal isoxsuprine ad-
ministration, isoxsuprine or 0.04 M saline was admin-
istered intravenously for 3 hours to term pregnant and
age-matched virgin rats. Isoxsuprine infusion significantly
increased plasma glucose and insulin concentrations and
decreased hepatic glycogen stores in both. Compared to
rat pups of saline infused mothers, pups of isoxsuprine
infused mothers had significantly elevated plasma glucose
concentrations for the first 4 hours of life and plasma
insulin concentrations for the first two. Plasma glucose
concentrations for the offspring of isoxsuprine treated
mothers then decreased significantly and remained so
until 16 hours of age. Hepatic glycogen concentrations
were significantly iess in rat pups of isoxsuprine treated
mothers at birth and for the first 4 hours of life. In a
limited number of studies, isoxsuprine was present at
birth in substantial quantities (80-85% of maternal
levels) in the plasma of rat pups of isoxsuprine infused
mothers. These data suggest that maternal isoxsuprine
therapy mobilizes hepatic glycogen and resultsin maternal
hyperglycemia. Maternal isoxsuprine infusion may di-
rectly deplete fetal hepatic glycogen and result in transient
fetal and neonatal hyperglycemia. The in utero depletion
of glycogen and possibly, the early Stimulation of insulin
production may be responsible for the later significant
decreases in plasma glucose in the o ff spring of isoxsuprine
treated mothers.
Keywords: Glucose, hepatic glycogen, insulin, Isoxsuprine, maternal and neonatal rat.
Zusammenfassung
Isoxsuprine Infusion in Ratten. Einfluß auf das mütter-
liche, fetale und neonatale Glukose-Gleichgewicht
Um die Einwirkung der mütterlichen Isoxsuprin-Infusion
auf das Glukose-Gleichgewicht zu untersuchen, wurde
Isoxsuprin oder eine 0,04 M Kochsalzlösung über 3 Stun-
den intravenös an trächtige und gleichaltrige jungfräu-
liche Ratten verabreicht.
In beiden Gruppen wurde durch die Isoxsuprininfusion
die Blutzucker- und Insulinkonzentration signifikant er-
höht und die Leberglykogenmenge erniedrigt. Im Ver-
gleich mit den neugeborenen Ratten der mit Kochsalz be-
handelten Gruppe, hatten die neugeborenen Ratten der
mit Isoxsuprin behandelten Gruppe einen signifikant
höheren Blutzuckerwert während der ersten 4 Lebens-
stunden und eine erhöhte Insulinkonzentration während
der ersten 2 Lebensstunden. Der Blutzuckerwert der
neugeborenen Ratten der Isoxsuprin-behandelten Gruppe
fiel dann rasch ab und blieb so in den ersten 16 Lebens-
stunden. Die Glykogenkonzentration in der Leber war
signifikant niedriger bei der Geburt und in den ersten
4 Lebensstunden in neugeborenen Ratten der Isoxsuprin-
Gruppe. In einer kleinen Anzahl von Studien konnte
Isoxsuprin bei der Geburt im Serum von neugeborenen
Ratten, deren Mütter Isoxsuprin bekommen hatten, nach-
gewiesen werden (80-85% der mütterlichen Konzentra-
tion).
Diese Ergebnisse lassen vermuten, daß eine mütterliche
Isoxsuprin-Therapie Glykogen aus der Leber freisetzt, ge-
folgt von einer mütterlichen Hyperglykämie. Eine Isox-
suprin-Infusion der Mutter kann den Glykogengehalt der
fetalen Leber verringern, gefolgt von einer fetalen und
neonatalen Hyperglykämie.
Die Senkung des Glykogengehaltes in utero und mögli-
cherweise die frühe Anregung der Insulinproduktion
könnte für den späteren Abfall des Blutzuckerwertes in
den Nachkömmlingen der Isoxsuprin-behandelten Mütter
verantwortlich sein.
Schlüsselwörter: Glukose, Insulin, Isoxsuprine, Leberglykogen, mütterliche und neugeborene Ratten.
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Resume
Infusion d'isoxsuprine chez le rat: Alterations de ITiomeo-
stase glucosique maternelle, foetale et neonatale
Pour determiner le mecanisme de Talteration de l'homeo-
stase glucosique due a Tadministration d'isoxsuprine chez
la mere, on administre par voie i. v. pendant 3 heures de
Tisoxsuprine oü 0,04 M de serum physiologique a des rats
vierges et enceintes du meme äge. Dans les deux groupes
l.isoxsuprine a fait augmenter de fa^on significative la
concentration de glucose et d'insuline dans le plasma et
fait diminuer le glycogene hepatique. En comparant les
jeunes rats nes de meres perfusees au serum physiologique
avec les jeunes rats nes de meres perfusees a l'isoxsuprine
ces-derniers avaient une glycemie elevee pendant les 4
premieres heures de leur vie et une concentration d'insuline
elevee dans le plasma durant les 2 premieres heures.
La glycemie des jeunes rats nes de meres traitees a l'isox-
suprine a diminue de fa$on significative et s'est maintenue
jusqu'a leur 16 heures de vie.
La concentration de glycogene etait nettement plus basse
chez les jeunes rats nes de meres traitees a l'isoxsuprine a
la naissance et durant les 4 premieres heures de vie. Dans
un nombre limite d'etudes, l'isoxsuprine etait present ä la
naissance dans le serum des jeunes rats (68-85% de la
concentration maternelle) dont les meres avaient ete
perfusees a l'isoxsuprine. Ce resultat laisse pense qu'une
therapie a l'isoxsuprine chez la mere mobilise le glycogene
hepatique et provoque une hyperglycemie chez cette
derniere. L'infusion d'isoxsuprine chez la mere peut
directement diminuer le glycogene hepatique foetale avec
comme resultat une hyperglycemie foetale et neonatale
transitoire. II est possible qüe la diminution du glycogene
au niveau uterin et la Stimulation prealable de la produc-
tion d'insuline soient responsable de la diminution con-
secutive du glucose plasmatique chez les jeunes rats nes
des meres traitees a l'isoxsuprine.
Mots-cles: Glucose, glycogene, hepatique, insuline, isoxsuprine, jeunes rats, rats meres.
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